Your browser doesn't support javascript.
Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancer.
Couderc, Anne-Laure; Ninove, Laetitia; Nouguerède, Emilie; Rey, Dominique; Rebroin, Marina; Daumas, Aurélie; Tomasini, Pascale; Greillier, Laurent; Salas, Sebastien; Duffaud, Florence; Dahan, Laetitia; Duluc, Muriel; Garcia, Marie-Eve; Pluvy, Johan; Chaléat, Solène; Farnault, Laure; Venton, Geoffroy; Fourié, Toscane; Nurtop, Elif; de Lamballerie, Xavier; Villani, Patrick; Charrel, Remi; Correard, Florian.
  • Couderc AL; Internal Medicine, Geriatrics and Therapeutic Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France; Aix-Marseille University, CNRS, EFS, ADES, Marseille, France; Coordination Unit for Geriatric Oncology (UCOG), PACA West, France. Electronic address: anne-laure.couderc@ap-hm.fr.
  • Ninove L; Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, 13005 Marseille, France.
  • Nouguerède E; Internal Medicine, Geriatrics and Therapeutic Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France; Coordination Unit for Geriatric Oncology (UCOG), PACA West, France.
  • Rey D; Internal Medicine, Geriatrics and Therapeutic Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France; Coordination Unit for Geriatric Oncology (UCOG), PACA West, France.
  • Rebroin M; Pharmacy Department, AP-HM, Marseille, France.
  • Daumas A; Internal Medicine, Geriatrics and Therapeutic Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
  • Tomasini P; Multidisciplinary Oncology and Therapeutic Innovations Department, AP-HM, Marseille, France.
  • Greillier L; Multidisciplinary Oncology and Therapeutic Innovations Department, AP-HM, Marseille, France.
  • Salas S; Oncology Unit, AP-HM, Marseille, France.
  • Duffaud F; Oncology Unit, AP-HM, Marseille, France.
  • Dahan L; Hepato-Gastro-Enterolgy Unit, CHU Timone, AP-HM, Marseille, France.
  • Duluc M; Hepato-Gastro-Enterolgy Unit, CHU Timone, AP-HM, Marseille, France.
  • Garcia ME; Multidisciplinary Oncology and Therapeutic Innovations Department, AP-HM, Marseille, France.
  • Pluvy J; Multidisciplinary Oncology and Therapeutic Innovations Department, AP-HM, Marseille, France.
  • Chaléat S; Multidisciplinary Oncology and Therapeutic Innovations Department, AP-HM, Marseille, France.
  • Farnault L; Haematology and Cellular Therapy Department, AP-HM, Marseille, France.
  • Venton G; Haematology and Cellular Therapy Department, AP-HM, Marseille, France.
  • Fourié T; Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, 13005 Marseille, France.
  • Nurtop E; Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, 13005 Marseille, France.
  • de Lamballerie X; Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, 13005 Marseille, France.
  • Villani P; Internal Medicine, Geriatrics and Therapeutic Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France; Aix-Marseille University, CNRS, EFS, ADES, Marseille, France.
  • Charrel R; Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, 13005 Marseille, France.
  • Correard F; Pharmacy Department, AP-HM, Marseille, France.
J Geriatr Oncol ; 13(6): 850-855, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1851497
ABSTRACT

PURPOSE:

The COVID-19 vaccination campaign began in December 2020, in France, and primarily targeted the oldest people. Our study aimed to determine the level of acceptance of vaccination in a population of older patients with cancer.

METHODS:

From January 2021, we offered vaccination with the BNT162b2 COVID-19 vaccine to all patients 70 years and older referred to our geriatric oncology center in Marseille University Hospital (AP-HM) for geriatric assessment before initiation of an oncological treatment. Objectives were to evaluate acceptance rate of COVID-19 vaccination and to assess vaccine safety, reactogenicity, and efficacy two months after the first dose.

RESULTS:

Between January 18, 2021 and May 7, 2021, 150 older patients with cancer were offered vaccination after a geriatric assessment. The majority were men (61.3%), with a mean age of 81 years. The two most frequent primary tumors were digestive (29.4%) and thoracic (18%). The vaccine acceptance rate was 82.6% and the complete vaccination rate (2 doses) reached 75.3%. Among the vaccinated patients, 15.9% reported mild side effects after the first dose and 23.4% after the second dose, mostly arm pain and fatigue. COVID-19 cases were observed in 5.1% of vaccinated patients compared with 16.7% in unvaccinated patients. Of the 22 vaccinated patients who agreed to have their serum tested, 15 had antibodies against the spike protein at day 21 after the first dose.

CONCLUSION:

Our study showed a high acceptance rate of COVID-19 vaccination, with good tolerance in this frail population. These results highlight the benefits of organizing vaccination campaigns at the very beginning of oncological management in older patients. CLINICAL TRIAL REGISTRATION This study was registered May 23, 2019 in ClinicalTrials.gov (NCT03960593).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 / Neoplasms Type of study: Randomized controlled trials Topics: Vaccines Limits: Aged / Female / Humans / Male Language: English Journal: J Geriatr Oncol Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 / Neoplasms Type of study: Randomized controlled trials Topics: Vaccines Limits: Aged / Female / Humans / Male Language: English Journal: J Geriatr Oncol Year: 2022 Document Type: Article